Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional HPV Vaccines for Recalcitrant Warts
NCT05383625Phase 3Completed
- Sponsor
- Zagazig University
- Start
- Sep 2020
- Primary completion
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of qHPV vaccine and human papillomavirus type 16 L1 capsid protein antigen in viral warts (3 arms), sponsored by Zagazig University. Primary endpoint: Therapeutic response at 12 weeks. Started Sep 2020; status: completed.
02
Drugs
qHPV vaccinehuman papillomavirus type 16 L1 capsid protein antigen
03
Conditions
viral warts
Beyond the preview
Go deeper on NCT05383625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383625.